List of Excipients in Branded Drug ONZETRA XSAIL

Onzetra Xsail Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Onzetra Xsail is a breath-powered intranasal powder containing sumatriptan succinate for acute migraine treatment. Its commercial differentiation depends less on the active ingredient, which is generic and mature, than on powder engineering, nasal tolerability, dose consistency, and the proprietary delivery device. The strongest excipient opportunities are carrier optimization, improved powder dispersion, reduced nasal irritation, and reformulation into a lower-cost or more convenient device platform.

The principal commercial risks are device-related manufacturing complexity, limited differentiation from established sumatriptan products, possible patent coverage around the delivery system, and the absence of a large regulatory exclusivity barrier for the active ingredient.

What is Onzetra Xsail and how does its formulation work?

Onzetra Xsail is approved as a nasal powder containing 11 mg of sumatriptan per nosepiece. The product uses a reusable breath-powered device and disposable nosepieces. The patient exhales through the device, which disperses the powder into the nasal cavity. The FDA approved Onzetra Xsail under NDA 207946 in January 2016 for the acute treatment of migraine with or without aura in adults. It is not indicated for migraine prevention. (U.S. Food and Drug Administration [FDA], 2016a)

The product relies on three technical components:

1. Sumatriptan succinate as the active pharmaceutical ingredient.
2. A respirable or dispersible nasal powder formulation.
3. A breath-powered delivery device that generates the airflow needed to distribute the powder.

The dosage form avoids liquid preservatives, metered liquid pumps, and propellants. The device also differentiates Onzetra from conventional sumatriptan nasal sprays.

Known formulation characteristics

FDA labeling identifies the product as sumatriptan succinate nasal powder and identifies mannitol as an inactive ingredient. Mannitol functions primarily as a bulking and carrier excipient. Its low hygroscopicity, established pharmaceutical use, and acceptable nasal safety profile make it suitable for a dry-powder nasal system. (FDA, 2016b)

The key quality attributes are:

Quality attribute	Commercial relevance
Particle-size distribution	Controls powder entrainment, nasal deposition, and lung-exposure risk
Bulk density	Affects dose loading and dispersion through the device
Flowability	Determines dose uniformity and manufacturing efficiency
Moisture content	Influences agglomeration, chemical stability, and device performance
Electrostatic charge	Can cause powder retention in the nosepiece or device
API-to-carrier uniformity	Controls delivered dose across individual nosepieces
Nasal residence time	Affects absorption and local tolerability
Dissolution rate	Influences onset of systemic exposure
Microbial quality	Important even though the product is dry and nonsterile

Which excipients are used in Onzetra Xsail?

The publicly identified excipient is mannitol. The product’s commercial performance therefore depends on the physical interaction between sumatriptan succinate and mannitol rather than on a large multifunctional excipient system.

Mannitol can provide several advantages:

• It dilutes the active ingredient to improve dose uniformity.
• It improves powder handling compared with very low-dose API-only systems.
• It can reduce cohesion between API particles.
• It has a relatively low tendency to absorb atmospheric moisture.
• It supports a dry-powder presentation without preservatives.

Mannitol also creates formulation constraints. Excessive carrier content can increase the powder mass delivered to the nose, reduce device efficiency, and leave a greater residue in the nasal cavity. Insufficient carrier content can produce poor dose uniformity, electrostatic retention, and inconsistent plume formation.

Excipient functions that matter most

The optimal excipient system should improve four commercial outcomes: consistent dose delivery, low nasal irritation, rapid dissolution, and stable performance across humidity conditions.

A development program should evaluate:

• Mannitol grade and particle morphology.
• Spray-dried versus milled carrier material.
• Crystalline versus partially amorphous carrier structure.
• Carrier-to-API ratio.
• Surface treatment with a low-level dispersibility modifier.
• Moisture-control packaging.
• Powder adhesion to the nosepiece and device components.
• Delivered dose after storage and repeated handling.

What excipients could improve Onzetra Xsail?

The strongest opportunities are incremental reformulations rather than a wholesale replacement of mannitol.

Mannitol optimization

Mannitol remains the most commercially practical starting point. The development opportunity is to select a grade with:

• Narrow particle-size distribution.
• Low residual moisture.
• Low electrostatic charge.
• Controlled surface roughness.
• Consistent bulk density.
• Low lot-to-lot variability.

A more tightly controlled mannitol grade could improve content uniformity and reduce failed-dose risk without requiring a new pharmacologic claim.

Trehalose and other sugar carriers

Trehalose could be evaluated as a secondary carrier or partial replacement for mannitol. It may improve powder structure and dissolution, but its hygroscopicity can create stability and flow problems. Trehalose would require more aggressive moisture-control packaging and may increase the risk of agglomeration.

Lactose is widely used in inhaled powders, but its suitability for Onzetra would depend on nasal tolerability, particle engineering, regulatory precedent, and potential sensitivity to particle-size variation. Lactose also creates additional considerations for patients with milk-protein sensitivity, even though pharmaceutical lactose is generally highly purified.

Amino-acid dispersibility modifiers

Leucine, glycine, and related amino acids can improve powder dispersibility by reducing surface cohesion and modifying particle surface energy. Leucine is particularly relevant to pulmonary dry-powder systems, but intranasal use would require focused local-tolerance studies and validation of its effect on sumatriptan dissolution.

A low concentration of leucine could create a more dispersible powder without materially increasing dose mass. The commercial value would be highest if it allowed a smaller nosepiece, fewer inhalation maneuvers, or more reliable delivery in patients with weak exhalation force.

Cyclodextrins and solubility modifiers

Cyclodextrins could improve dissolution or alter local drug solubilization. Their use would require careful assessment of:

• Nasal epithelial tolerability.
• Local osmotic effects.
• Potential changes in absorption rate.
• Powder hygroscopicity.
• Cost and manufacturing complexity.

Cyclodextrins are more likely to be commercially useful in a new formulation seeking a faster-onset or lower-dose profile than in a simple line extension.

Mucoadhesive excipients

Mucoadhesive polymers could increase nasal residence time, but they may also delay clearance, increase local irritation, and interfere with the breath-powered delivery plume. Polymers such as chitosan or selected cellulose derivatives could support a differentiated formulation, but this strategy would carry greater regulatory and clinical risk than mannitol optimization.

A mucoadhesive version would need to demonstrate a meaningful benefit, such as faster onset, longer exposure, or lower dose. An incremental change in nasal residence time alone would likely have limited commercial value.

What formulation patents protect Onzetra Xsail?

The relevant intellectual-property estate is expected to cover both the formulation and the delivery system. The formulation claims may address:

• Sumatriptan succinate powder.
• Mannitol or another carrier excipient.
• Particle-size ranges.
• Powder loading per nosepiece.
• Breath-powered dispersion.
• Nasal deposition.
• Methods for treating migraine.

The device claims may address:

• The reusable inhalation body.
• Disposable nosepieces.
• Airflow pathways.
• Powder release mechanisms.
• Patient exhalation through the device.
• Coordination of exhaled airflow and nasal delivery.

Patent protection should be analyzed separately from FDA regulatory exclusivity. Approval in 2016 did not create a new chemical entity exclusivity period because sumatriptan had been previously approved. Any applicable three-year exclusivity would have been tied to the approved dosage form or clinical investigation and would not prevent later development of a different sumatriptan product outside the protected scope.

The Orange Book should be reviewed for current patent listings associated with NDA 207946, including patent expiration dates, pediatric exclusivity adjustments, and any certifications submitted by an ANDA applicant. FDA Orange Book listings are the controlling source for patents submitted to FDA for approved drug products. (FDA, 2024a)

When does Onzetra Xsail lose exclusivity?

Onzetra Xsail did not receive five-year new chemical entity exclusivity because sumatriptan was already approved. Its principal barriers are therefore patents, device know-how, regulatory development costs, and commercial execution.

The practical exclusivity timeline is:

Exclusivity category	Relevance to Onzetra Xsail
New chemical entity exclusivity	Not applicable to previously approved sumatriptan
Three-year clinical-investigation exclusivity	Potentially applicable after the 2016 approval, subject to FDA determination
Pediatric exclusivity	Depends on FDA-recognized pediatric studies
Formulation patents	May cover powder composition or particle characteristics
Device patents	May cover the breath-powered delivery system
Method-of-use patents	May cover acute migraine treatment or administration conditions
Trade secrets	May protect blending, filling, and powder-conditioning processes
Regulatory device know-how	May delay competitive replication even after patents expire

A generic applicant could pursue an ANDA if it could establish pharmaceutic equivalence and address the device component. If the product’s device is considered integral to the drug product, the applicant may face additional design, comparative-use, and human-factors obligations.

What Paragraph IV challenges and generic entry risks exist?

A Paragraph IV applicant could challenge listed patents by asserting that they are invalid, unenforceable, or not infringed. The most plausible challenge points would involve:

• Obviousness of combining sumatriptan with mannitol.
• Anticipation by earlier nasal powder formulations.
• Lack of written description for narrow particle-size or airflow claims.
• Noninfringement through a different powder carrier.
• Use of a different nasal delivery device.
• Design-around of disposable nosepiece geometry.
• Lack of patent-term extension or improper Orange Book listing.

The product’s generic risk is lower than for an ordinary sumatriptan tablet or liquid nasal spray because a competitor must reproduce or legally substitute the delivery system. That risk is not eliminated. A competing manufacturer could use a different breath-powered device, a passive insufflation device, or a conventional nasal powder applicator.

Generic launch scenarios

Scenario	Likely commercial effect
No ANDA challenge and no competing device	Continued niche protection through complexity and brand recognition
Paragraph IV challenge with a successful noninfringement position	Potential early generic entry before all patent expirations
Authorized generic or licensed device copy	Rapid price erosion with limited clinical differentiation
Alternative sumatriptan nasal powder	Moderate substitution risk if onset and tolerability are comparable
New liquid or inhaled migraine product	Indirect competitive pressure rather than direct substitution
Combination migraine products	Higher threat among patients seeking broader symptom control

How strong is the Onzetra Xsail patent estate?

The estate is likely stronger around the integrated product platform than around the excipient itself.

Higher-value protection

• Device architecture.
• Breath-powered powder dispersion.
• Nosepiece design.
• Integration of the formulation with the device.
• Manufacturing controls needed to achieve consistent delivery.

Weaker or more vulnerable protection

• Mannitol as a carrier.
• Generic dry-powder nasal delivery concepts.
• Broad claims to sumatriptan powder.
• Routine particle-size optimization.
• Conventional migraine treatment claims.

A formulation claim limited to sumatriptan and mannitol may face obviousness pressure if earlier publications disclose nasal powders, sugar carriers, or sumatriptan nasal delivery. Device claims may be more defensible where they require a specific airflow path, release mechanism, or coordinated exhalation step.

What commercial opportunities exist for Onzetra Xsail excipients?

1. Premium reformulation

A reformulated powder could target:

• Faster onset.
• Lower nasal irritation.
• More complete dose delivery.
• Reduced powder residue.
• Fewer patient handling steps.

A meaningful improvement could support a new product presentation, new patent filings, and differentiated payer messaging.

2. Lower-cost platform

The largest commercial opportunity may be manufacturing simplification. A lower-cost nosepiece, simplified filling process, or more robust powder could improve margins without changing the active ingredient.

Potential targets include:

• Standardized mannitol feedstock.
• Continuous blending.
• Automated nosepiece filling.
• Lower-cost moisture-barrier packaging.
• Fewer device components.
• More forgiving powder-flow specifications.

3. Multi-dose or refill presentation

A multi-dose device could reduce packaging waste and improve adherence. The technical risks include dose segregation, humidity ingress, cleaning, cross-contamination, and dose-count accuracy. A refill cartridge system could create recurring device revenue but would require substantial human-factors testing.

4. International expansion

Dry-powder nasal sumatriptan may have an opportunity in markets where patients prefer nonoral migraine treatment but do not want injections. Geographic expansion would require review of:

• Local medicine classification.
• Device registration requirements.
• Patent status.
• Nasal powder safety data.
• Translation and usability requirements.
• Reimbursement for non-tablet migraine treatments.

US approval does not automatically establish European, Canadian, Japanese, or Australian regulatory acceptance. The device-drug combination may receive different regulatory treatment in each jurisdiction.

5. Licensing and co-development

Potential partners include:

• Nasal-device manufacturers.
• Contract development and manufacturing organizations.
• Specialty migraine companies.
• Generic companies with nasal-device capabilities.
• Excipient suppliers with engineered-powder platforms.

The most defensible licensing package would combine formulation know-how, device rights, filling technology, and clinical comparability data. Licensing only the mannitol-based formulation would provide weaker negotiating leverage because the excipient itself is not difficult to source.

What FDA regulatory issues affect an Onzetra Xsail reformulation?

A reformulation could require one of several FDA pathways:

• A supplemental NDA if the formulation remains within the approved product framework.
• A new NDA or 505(b)(2) application if the formulation, device, or clinical profile changes materially.
• An ANDA only if the applicant can establish the required equivalence to the reference product.
• A combination-product review involving both drug and device requirements.

The main regulatory studies would likely include:

• Delivered-dose uniformity.
• Spray or plume characterization.
• Particle-size distribution.
• In vitro deposition.
• Comparative pharmacokinetics.
• Local nasal tolerability.
• Device usability.
• Stability under accelerated and long-term conditions.
• Extractables and leachables from nosepiece materials.
• Dose delivery across patient-use conditions.

The most efficient strategy is to preserve the approved dose and route while changing only the carrier grade, powder-processing parameters, or device components that can be bridged with comparative data.

What manufacturing and intellectual-property barriers matter most?

The main manufacturing barrier is not synthesis of sumatriptan. It is reproducible production of a low-mass, electrostatically active powder that disperses consistently through a patient-operated device.

Critical process controls include:

• API micronization.
• Carrier sieving or classification.
• Blend-order control.
• Relative humidity during processing.
• Fill-weight control.
• Powder transfer losses.
• Nosepiece sealing.
• Packaging moisture ingress.
• Device airflow performance.

Trade-secret protection may be valuable even where patents are weak. A manufacturer with a validated blending and filling process could maintain a cost advantage through lower rejection rates and tighter delivered-dose performance.

How does Onzetra Xsail compare with other sumatriptan products?

Product type	Main advantage	Main limitation	Excipient opportunity
Oral sumatriptan tablet	Low cost and familiarity	Slower or unreliable absorption during nausea	Rapid-disintegration tablets and taste masking
Sumatriptan nasal spray	Simple administration	Liquid formulation and nasal taste	Preservative-free and low-volume delivery
Sumatriptan injection	High and reliable exposure	Needle burden and training	Autoinjector usability
Onzetra Xsail	Needle-free dry powder and breath-powered delivery	Device complexity and handling	Better powder dispersion and simpler device
Other nasal migraine products	Alternative mechanisms or delivery platforms	Higher development and reimbursement barriers	Mucoadhesion, permeation enhancement, or combination therapy

Onzetra’s competitive position depends on whether patients value a needle-free option that can deliver systemic sumatriptan without relying on gastrointestinal absorption. Its excipient strategy should therefore support rapid, reliable nasal delivery rather than simply reduce ingredient cost.

Key Takeaways

• Onzetra Xsail is a sumatriptan succinate nasal powder delivered through a breath-powered device.
• Mannitol is the principal publicly identified inactive ingredient and is the logical starting point for formulation optimization.
• The strongest technical opportunities are improved powder flow, lower moisture sensitivity, better dose uniformity, and reduced nasal residue.
• Leucine, trehalose, glycine, cyclodextrins, and selected mucoadhesive systems are potential development options, but each adds regulatory and stability risk.
• The integrated device-formulation platform is likely more defensible than a basic sumatriptan-mannitol composition.
• Generic entry risk is moderated by device complexity but remains material if competitors design around the delivery system.
• The best commercial opportunities are premium reformulation, lower-cost manufacturing, refillable devices, international licensing, and partnerships with nasal-device manufacturers.
• FDA Orange Book listings, patent litigation records, and current product commercialization status should be reviewed before any acquisition, licensing, or launch decision.

FAQs

Is mannitol safe for nasal delivery in Onzetra Xsail?

Mannitol is an established pharmaceutical excipient and is identified in FDA product information for Onzetra Xsail. Its suitability depends on concentration, particle characteristics, local tolerability, and delivered-dose performance.

Could a competitor replace mannitol and avoid Onzetra patents?

Potentially. A competitor could use a different carrier or an API-only powder if it achieves equivalent delivery performance. Avoiding a mannitol limitation would not necessarily avoid separate device or method-of-use claims.

Can Onzetra Xsail be converted into a conventional nasal spray?

A liquid spray would be a different formulation and could require new stability, device, pharmacokinetic, and local-tolerability data. It would also lose some of the commercial differentiation associated with dry-powder delivery.

Would a new excipient create new patentable subject matter?

Yes, if the excipient produces a non-obvious technical result such as improved deposition, faster onset, lower variability, or better stability. Patent strength would depend on comparative data and claim scope.

What is the most attractive commercial reformulation?

A lower-cost, more humidity-resistant powder using an optimized mannitol grade and a simplified nosepiece is likely the lowest-risk opportunity. A faster-onset or lower-irritation formulation could offer greater differentiation but would require more extensive clinical and regulatory support.

References

1. U.S. Food and Drug Administration. (2016a). ONZETRA Xsail: Sumatriptan succinate nasal powder, NDA 207946 approval letter and prescribing information.
2. U.S. Food and Drug Administration. (2016b). ONZETRA Xsail prescribing information.
3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2024b). Inactive ingredient database.
5. U.S. Food and Drug Administration. (2024c). Guidance for industry: Nasal spray and inhalation solution, suspension, and spray drug products: Chemistry, manufacturing, and controls documentation.